1. A PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTORMODIFIED T CELLS DIRECTED AGAINST CD19 IN PATIENTS WITH RELAPSED OR REFRACTORYCD19(+) B CELL LYMPHOMAS: INTERIM ANALYSIS. (June 2017) Authors: Ying, Z.; Xiang, X.; Song, Y.; Ding, N.; Lin, Y.; Zheng, W.; Wang, X.; Lin, N.; Tu, M.; Xie, Y.; Zhang, C.; Liu, W.; Deng, L.; Liu, Y.; Yue, Y.; Yu, X.; Liu, H.; Duan, P.; Chen, F.; Wu, X. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FIRST‐LINE L‐ASPARAGINASE‐BASED CHEMOTHERAPY PLUS RADIOTHERAPY IS ACTIVE IN STAGE I/II EXTRANODAL NK/T‐CELL LYMPHOMA: RESULTS FROM PEKING UNIVERSITY CANCER HOSPITAL. (June 2017) Authors: Song, Y.; Jia, J.; Wu, M.; Leng, X.; Lin, N.; Xie, Y.; Zheng, W.; Wang, X.; Ping, L.; Tu, M.; Ying, Z.; Zhang, C.; Liu, W.; Deng, L.; Zhu, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗